These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 9258099

  • 21. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
    Lodding P, Aus G, Bergdahl S, Frösing R, Lilja H, Pihl CG, Hugosson J.
    J Urol; 1998 Mar; 159(3):899-903. PubMed ID: 9474178
    [Abstract] [Full Text] [Related]

  • 22. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [Abstract] [Full Text] [Related]

  • 23. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer.
    Henderson RJ, Eastham JA, Culkin DJ, Kattan MW, Whatley T, Mata J, Venable D, Sartor O.
    J Natl Cancer Inst; 1997 Jan 15; 89(2):134-8. PubMed ID: 8998182
    [Abstract] [Full Text] [Related]

  • 24. [Systematic ultrasound guided transrectal core prostate biopsy based on serum level of prostate-specific antigen].
    Yamaguchi S, Baba Y, Naito K.
    Hinyokika Kiyo; 1997 Sep 15; 43(9):641-5. PubMed ID: 9365843
    [Abstract] [Full Text] [Related]

  • 25. [The role of the absolute value and "density" of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between PSA, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy].
    Di Donna A, Bazzocchi M, Guerra UP, Bendini M, De Biasi F, Caminiti F, Delendi M.
    Radiol Med; 1993 Sep 15; 85(1-2):84-9. PubMed ID: 7683136
    [Abstract] [Full Text] [Related]

  • 26. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer.
    Ito K, Yamamoto T, Kubota Y, Suzuki K, Fukabori Y, Kurokawa K, Yamanaka H.
    Urology; 2000 Aug 01; 56(2):278-82. PubMed ID: 10925094
    [Abstract] [Full Text] [Related]

  • 27. Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L, García Mediero JM, González Gancedo P, Tabernero A, Lozano D, López-Tello JJ, Alonso-Dorrego JM, Núñez C, Picazo ML, Madero R, De La Peña JJ.
    World J Urol; 2004 Jun 01; 22(2):124-31. PubMed ID: 14986047
    [Abstract] [Full Text] [Related]

  • 28. [Value of prostate-specific antigen density and transitional-zone prostate-specific antigen density in the diagnosis of prostate cancer].
    Martínez Jabaloyas JM, García Morata F, Villamón Fort R, Pastor Hernández F, Gil Salom M, García Sisamón F.
    Actas Urol Esp; 2003 Jun 01; 27(6):442-9. PubMed ID: 12918151
    [Abstract] [Full Text] [Related]

  • 29. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population.
    Kobayashi T, Nishizawa K, Ogura K, Mitsumori K, Ide Y.
    Urology; 2004 Apr 01; 63(4):727-31. PubMed ID: 15072889
    [Abstract] [Full Text] [Related]

  • 30. Combined use of prostate-specific antigen derivatives decreases the number of unnecessary biopsies to detect prostate cancer.
    Ozen H, Aygün C, Ergen A, Sözen S, Aki FT, Uygur MC.
    Am J Clin Oncol; 2001 Dec 01; 24(6):610-3. PubMed ID: 11801765
    [Abstract] [Full Text] [Related]

  • 31. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.
    Ellis WJ, Chetner MP, Preston SD, Brawer MK.
    J Urol; 1994 Nov 01; 152(5 Pt 1):1520-5. PubMed ID: 7523710
    [Abstract] [Full Text] [Related]

  • 32. Prostate cancer detection at low prostate specific antigen.
    Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R.
    J Urol; 2000 Mar 01; 163(3):806-12. PubMed ID: 10687982
    [Abstract] [Full Text] [Related]

  • 33. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug 01; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 34. The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml.
    Morote J, Trilla E, Esquena S, Serrallach F, Abascal JM, Muñoz A, Id M'Hammed Y, de Torres IM.
    Eur Urol; 2002 Oct 01; 42(4):333-7. PubMed ID: 12361897
    [Abstract] [Full Text] [Related]

  • 35. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
    Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schröder FH.
    J Urol; 1997 Jun 01; 157(6):2191-6. PubMed ID: 9146612
    [Abstract] [Full Text] [Related]

  • 36. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D, Kamil ST, Pakasi LS.
    Gan To Kagaku Ryoho; 2000 May 01; 27 Suppl 2():563-70. PubMed ID: 10895211
    [Abstract] [Full Text] [Related]

  • 37. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
    Luboldt HJ, Bex A, Swoboda A, Hüsing J, Rübben H, Early Detection Project Group of the German Urological Association.
    Eur Urol; 2001 Feb 01; 39(2):131-7. PubMed ID: 11223671
    [Abstract] [Full Text] [Related]

  • 38. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B, Alkibay T, Tuncel A, Bozkirli I.
    Can J Urol; 2000 Oct 01; 7(5):1104-9. PubMed ID: 11114873
    [Abstract] [Full Text] [Related]

  • 39. Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range.
    Kefi A, Irer B, Ozdemir I, Tuna B, Goktay Y, Yorukoğlu K, Esen A.
    Urol Int; 2005 Oct 01; 75(3):222-6. PubMed ID: 16215309
    [Abstract] [Full Text] [Related]

  • 40. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.
    Chiu PK, Teoh JY, Lee WM, Yee CH, Chan ES, Hou SM, Ng CF.
    Investig Clin Urol; 2016 Sep 01; 57(5):336-42. PubMed ID: 27617315
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.